Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV — United States, 2022 | MMWR
![Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]](https://www.menveohcp.com/content/dam/cf-pharma/hcp-menveo/en_US/booster/2-vial-seroresponse-rates-29-days-Mobile.svg "Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]")
Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine | Infectious Diseases and Therapy
MenACWY Updates: Give 2 Doses to Strengthen Adolescents Immunizations - CPP | National Vaccine Buying Group | Vaccine Group Purchase Organization
Parents and Teens – National Meningitis Association
Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands | PLOS ONE
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years | BMC Infectious Diseases
MenACWY Frenquently Asked Questions - HSE.ie
ACIP provides recommendations on meningococcal vaccination
Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods - ScienceDirect
Public Health Agency on X: "If your planning on going to university or college make sure your teenage immunisations are up-to-date. It's also worth checking if you got your MMR and HPV.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years | BMC Infectious Diseases
Dosing & Infusion Instruction | Soliris® (eculizumab) HCP
Subject disposition and vaccination schedule. The MenACWY-CRM... | Download Scientific Diagram
Full article: Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
Univariate sensitivity analysis for MenACWY + MenACWY compared with... | Download Scientific Diagram
ACIP Updates Recommendations for Meningococcal Vaccination | AAFP
Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children - ScienceDirect
MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults - ScienceDirect
FAQs on MenACWY vaccine | Meningitis Now | Meningitis Now
Meningococcal Disease — Kimberly Coffey Foundation
Immunisation for teenagers between 14 and 18 years old | nidirect
